688393.SHG Guangzhou LBP Medicine Science & Technology Co Ltd
- Market cap
- CNY 1.71B
- P/E
- -
- P/B
- 1.40x
- ROE
- 0.1%
- Dividend yield
- 0.56%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688393.SHG undervalued?
Graham numberThe Graham number of Guangzhou LBP Medicine Science & Technology Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangzhou LBP Medicine Science & Technology Co Ltd fundamental analysis
No fundamental analysis for Guangzhou LBP Medicine Science & Technology Co Ltd yet.
Guangzhou LBP Medicine Science & Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangzhou LBP Medicine Science & Technology Co Ltd
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample pr…
Full company profileGuangzhou LBP Medicine Science & Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangzhou LBP Medicine Science & Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 241M | 260M | 306M | 355M | 375M | 439M | 507M | 497M | 471M | 347M | 343M |
| Gross Profit | 198M | 217M | 254M | 297M | 299M | 340M | 358M | 335M | 311M | 347M | 226M |
| Operating Income | 47.0M | 60.6M | 74.4M | 88.8M | 100M | 88.9M | 28.7M | 21.5M | 11.0M | -51.9M | 201K |
| EBITDA | 67.4M | 73.2M | 86.9M | 98.7M | 110M | 106M | 62.5M | 55.9M | 48.5M | -17.8M | -3.11M |
| Net Income | 46.0M | 48.3M | 61.5M | 74.0M | 84.7M | 79.8M | 42.7M | 40.1M | 21.3M | -45.0M | 1.53M |
| EPS | 0.66 | 0.69 | 0.88 | 1.06 | 1.09 | 0.85 | 0.45 | 0.42 | 0.23 | -0.48 | 0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 357M | 412M | 477M | 538M | 1.29B | 1.37B | 1.39B | 1.40B | 1.36B | 1.29B | 1.25B |
| Total Liabilities | 36.1M | 65.8M | 87.2M | 93.3M | 125M | 156M | 170M | 162M | 131M | 128M | 117M |
| Shareholders' Equity | 315M | 343M | 387M | 443M | 1.17B | 1.20B | 1.23B | 1.26B | 1.26B | 1.18B | 1.14B |
| Cash & Short-term Investments | 96.1M | 73.7M | 75.0M | 171M | 846M | 637M | 266M | 120M | 150M | 31.3M | 45.5M |
| Total Debt | - | - | - | - | 1.77M | 12.4M | 24.8M | 31.8M | 8.95M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 43.4M | 83.9M | 65.4M | 89.7M | 91.4M | 59.6M | 9.72M | 17.1M | 3.54M | 40.0M | - |
| Capital Expenditure | 15.8M | 33.4M | 43.9M | 35.5M | 62.4M | 143M | 72.2M | 37.7M | 23.6M | 23.2M | 29.6M |
| Free Cash Flow | 27.6M | 50.5M | 21.4M | 54.2M | 29.0M | -83.7M | -62.5M | -20.6M | -20.1M | 16.9M | -23.0M |
| Ratios | |||||||||||
| ROE | 14.6% | 14.1% | 15.9% | 16.7% | 7.3% | 6.6% | 3.5% | 3.2% | 1.7% | -3.8% | 0.1% |
| ROA | 12.9% | 11.7% | 12.9% | 13.8% | 6.6% | 5.8% | 3.1% | 2.9% | 1.6% | -3.5% | 0.1% |
| Net Profit Margin | 19.1% | 18.6% | 20.1% | 20.8% | 22.6% | 18.2% | 8.4% | 8.1% | 4.5% | -13.0% | 0.4% |
| Debt to Equity | - | - | - | - | 0.00x | 0.01x | 0.02x | 0.03x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangzhou LBP Medicine Science & Technology Co Ltd dividends
- Dividend yield
- 0.56%
- Forward dividend
- 0.10 CNY
- Payout ratio
- -
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 9.53M | 0.10 | - |
| 2024 | CNY 14.5M | 0.16 | 68.1% |
| 2023 | CNY 13.5M | 0.14 | 33.6% |
| 2022 | CNY 25.2M | 0.27 | 59.0% |
| 2021 | CNY 26.1M | 0.28 | 32.8% |
| 2020 | - | - | - |
| 2019 | CNY 17.5M | 0.25 | 23.7% |
| 2018 | 16.5M | 0.24 | 26.9% |
| 2017 | 21.0M | 0.30 | 43.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Guangzhou LBP Medicine Science & Technology Co Ltd
- Insiders 48.42%
- Institutions 6.83%
- Public & others 44.75%
- Shares outstanding 93.6M
- Free float 143M
Guangzhou LBP Medicine Science & Technology Co Ltd company profile
- Company name
- Guangzhou LBP Medicine Science & Technology Co Ltd
- Ticker
- 688393.SHG
- ISIN
- CNE1000043R4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 768
- Fiscal year end
- December
- Address
- No. 2, Kexin Street, Guangzhou, China, 510663
- Phone
- 86 20 3229 9997
- Website
- gzlbp.com
About Guangzhou LBP Medicine Science & Technology Co Ltd
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample preservation solutions, and automatic nucleic acid molecular hybridization instruments; fluorescence in situ hybridization products comprising auto-fish instruments, and AML1/ETO, EGFR, BCR/ABL fusion, PML/RARA, and TOP2A gene testing kits; and digital pathology products pathological medical image analysis processing systems, real-time microscopic visual field sharing systems, and bingli scanner. It also provides immunohistochemistry products including automatic antigen repair instrument and automatic immunocytochemical staining machine, as well as conversional pathology equipment. The company's products have applications in tumor screening, tumor subtyping, companion diagnostics, efficacy monitoring, and recurrence detection. It serves public hospitals, medical institutions, and pharmaceutical companies. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.
Guangzhou LBP Medicine Science & Technology Co Ltd management
4- Mr. Xiangting CaiChairman of the Board & GM · born 1964
- Mr. Quanneng HouCFO & Board Secretary · born 1983
- Sun HuaDeputy GM & Director · born 1973
- Aiping HuangAccounting Supervisor